Sharon Worcester

3 weeks ago | medscape.com | Sharon Worcester

CHICAGO — Can spotting an emerging ESR1 mutation early and changing first-line drugs before progression improve outcomes in patients with hormone receptor (HR)–positive, human epidermal growth factor receptor 2–negative advanced breast cancer? Interim findings from the SERENA-6 trial suggest that may be the case.

3 weeks ago | medscape.com | Sharon Worcester

The US Food and Drug Administration (FDA) has approved single-agent darolutamide (Nubeqa, Bayer Healthcare Pharmaceuticals, Inc.) for the treatment of metastatic castration–sensitive prostate cancer (mCSPC). Darolutamide, an androgen receptor inhibitor, was previously approved in combination with docetaxel chemotherapy for mCSPC.

1 month ago | medscape.com | Sharon Worcester

The American Society of Clinical Oncology (ASCO) and Google Cloud have recently launched an artificial intelligence (AI)–powered search tool to provide accurate and fast access to ASCO’s full library of evidence-based clinical guidelines, the society announced this week.

1 month ago | mdedge.com | Sharon Worcester

Rates of certain cancers in the United States — including breast, colorectal, and thyroid cancers — increased between 2010 and 2019 among patients aged less than 50 years, while overall cancer incidence and mortality rates did not increase, a new study found. Among the more than two million cases of early-onset cancer diagnosed during this period, 63.2% were in women, researchers reported recently in Cancer Discovery.

1 month ago | medscape.com | Sharon Worcester

Rates of certain cancers in the United States — including breast, colorectal, and thyroid cancers — increased between 2010 and 2019 among patients aged less than 50 years, while overall cancer incidence and mortality rates did not increase, a new study found. Among the more than two million cases of early-onset cancer diagnosed during this period, 63.2% were in women, researchers reported recently in Cancer Discovery.